ETHOSUXIMIDE

Post-LOE

ethosuximide

ANDAORALCAPSULE
Approved
Mar 2020
Lifecycle
Post-LOE
Competitive Pressure
30/100

Mechanism of Action

CLINICAL PHARMACOLOGY Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and…

Pharmacologic Class:

Anti-epileptic Agent

Indications (1)